Recombinant Human sTRAILR2/TNFRSF10B (Recombinant Human soluble Tumor Necrosis Factor Related Apoptosis-inducing Ligand Receptor-2; rHusTRAIL-R2);重组人可溶性诱导肿瘤坏死因子相关凋亡诱导配体受体2/TNFRSF10B
Synonyms
CD262; DR5; TNFRSF10B; CD262; CD262 antigen; death domain containing receptor for TRAIL/Apo-2L; Death receptor 5; DR5TRICK2B; Fas-like protein; KILLER/DR5; KILLERapoptosis inducing protein TRICK2A/2B; TNF-related apoptosis-inducing ligand receptor 2; TRAIL receptor 2; TRAIL-R2apoptosis inducing receptor TRAIL-R2; TRAILR2cytotoxic TRAIL receptor-2; TRICK2; TRICK2A; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; ZTNFR9
Purity
>97% by SDS-PAGE and HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. rHusTRAIL-R2 reduced the production of LPSinduced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10ng/ml) but in the presence of rHusTRAIL-R2, TRAIL-induced TNF is suppressed.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH7.4.
Endotoxin
Less than 1EU/μg of rHusTRAIL-R2 as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
Tumor necrosis factor-related apoptosis-inducing ligand Receptor 2 (TRAIL-R2) is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells. TRAIL-R2 has been shown to be associated with a decrease in the survival rates of breast cancer patients.